Skip to main content
SpringerLink
Log in

Traitement médical du cancer du sein métastatique

  • Conference paper
Cancer du sein

Abstrait

Dans le cancer du sein, l’apparition de métastases est signe d’incurabilité et relève d’un traitement médical dont deux modalités, l’hormonothérapie et la chimiothérapie, sont utilisées depuis des décennies et une, l’immunothérapie, d’utilisation récente, annonce les thérapies ciblées. L’efficacité des traitements disponibles constatée quotidiennement est temporaire, modeste individuellement mais somme toute bénéfique par leur diversité.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Rutqvist LE, Cedermark B, Glas U et al. (1990) Randomized trial of adjuvant tamoxifen combined with postoperative radiation therapy or adjuvant chemotherapy in postmenopausal breast cancer. Cancer 66: 89–96

    Article  PubMed  CAS  Google Scholar 

  2. Jensen EV, Block GE, Smith S, Kyser K, DeSombre ER (1971) Estrogen receptors and breast cancer response to adrenalectomy. Natl Cancer Inst Monogr 34: 55–70

    PubMed  CAS  Google Scholar 

  3. Jensen EV, Brecher PI, Numata M, Smith S, DeSombre ER (1975) Estrogen interaction with target tissues; two-step transfer of receptor to the nucleus. Methods Enzymol 36: 267–275

    Article  PubMed  CAS  Google Scholar 

  4. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687–1717

    Article  CAS  Google Scholar 

  5. Wittliff JL (1984) Steroid-hormone receptors in breast cancer. Cancer 53(3 Suppl): 630–643

    Article  PubMed  CAS  Google Scholar 

  6. Regan MM, Viale G, Mastropasqua MG et al. (2006) Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst 98: 1571–1581

    PubMed  CAS  Google Scholar 

  7. Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155–168

    PubMed  CAS  Google Scholar 

  8. Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17: 1474–1481

    PubMed  CAS  Google Scholar 

  9. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM (2003) Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases. J Clin Oncol 21: 1973

    Article  PubMed  CAS  Google Scholar 

  10. Thomson CS, Twelves CJ, Mallon EA, Leake RE (2002) Adjuvant ovarian ablation vs CMF chemotherapy in premenopausal breast cancer patients: trial update and impact of immunohistochemical assessment of ER status. Breast 11: 419–429

    Article  PubMed  CAS  Google Scholar 

  11. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy’s Hospital, London (1993) Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Lancet 341: 1293–1298

    Article  Google Scholar 

  12. Kristensen VN, Sorlie T, Geisler J et al. (2005) Gene Expression Profiling of Breast Cancer in Relation to Estrogen Receptor Status and Estrogen-Metabolizing Enzymes: Clinical Implications. Clin Cancer Res 11: 878s–883

    PubMed  CAS  Google Scholar 

  13. Beatson GT (1896) On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 104–107

    Google Scholar 

  14. Crump M, Sawka CA, DeBoer G et al. (1997) An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer. Breast Cancer Res Treat 44: 201–210

    Article  PubMed  CAS  Google Scholar 

  15. Klijn JGM, Blarney RW, Boccardo F et al. (2001) Combined Tamoxifen and Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Versus LHRH Agonist Alone in Premenopausal Advanced Breast Cancer: A Meta-Analysis of Four Randomized Trials. J Clin Oncol 19: 343–353

    PubMed  CAS  Google Scholar 

  16. Carlini P, Bria E, Giannarelli D et al. (2005) New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials. Cancer 104: 1335–1342

    Article  PubMed  CAS  Google Scholar 

  17. Mauri D, Pavlidis N, Polyzos NP, Ioannidis JPA (2006) Survival With Aromatase Inhibitors and Inactivators Versus Standard Hormonal Therapy in Advanced Breast Cancer: Meta-analysis. JNCI Cancer Spectrum 98: 1285–1291

    Article  CAS  Google Scholar 

  18. Howell A, Robertson JF, Abram P et al. (2004) Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22: 1605–1613

    Article  PubMed  CAS  Google Scholar 

  19. Robertson JF, Osborne CK, Howell A et al. (2003) Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 98: 229–238

    Article  PubMed  CAS  Google Scholar 

  20. Wilcken N, Hornbuckle J, Ghersi D (2003) Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev 2: CD002747

    Google Scholar 

  21. De Laurentiis M, Arpino G, Massarelli E et al. (2005) A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 1113: 4741–4748

    Article  Google Scholar 

  22. Ellis MJ, Tao Y, Young O et al. (2006) Estrogen-Independent Proliferation Is Present in Estrogen-Receptor HER2-Positive Primary Breast Cancer After Neoadjuvant Letrozole. J Clin Oncol 24: 3019–3025

    Article  PubMed  CAS  Google Scholar 

  23. Smith IE, Dowsett M, Ebbs SR et al. (2005) Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23: 5108–5116

    Article  PubMed  CAS  Google Scholar 

  24. Jones D, Ghersi D, Wilcken N (2006) Addition of drug/s to a chemotherapy regimen for metastatic breast cancer. Cochrane Database Syst Rev 3: CD003368

    PubMed  CAS  Google Scholar 

  25. Fossati R, Confalonieri C, Torri V et al. (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16: 3439–3460

    PubMed  CAS  Google Scholar 

  26. Carrick S, Parker S, Wilcken N et al. (2005) Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2: CD003372

    PubMed  Google Scholar 

  27. Sledge GW, Neuberg D, Bernardo P et al. (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as frontline chemotherapy for metastatic breast cancer: an intergroup trial (El 193). J Clin Oncol 21: 588–592

    Article  PubMed  Google Scholar 

  28. Alba E, Martin M, Ramos M et al. (2004) Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol 22: 2587–2593

    Article  PubMed  CAS  Google Scholar 

  29. Citron ML, Berry DA, Cirrincione C et al. (2003) Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21: 1431–1439

    Article  PubMed  CAS  Google Scholar 

  30. Ghersi D, Wilcken N, Simes RJ (2005) A systematic revie of taxane-containing regimens for metastatic breast cancer. Br J Cancer 93: 293–301

    Article  PubMed  CAS  Google Scholar 

  31. Seidman AD (2005) « Will Weekly Work»? Seems to Be So. J Clin Oncol 23: 5873–5874

    Article  PubMed  Google Scholar 

  32. Green MC, Buzdar AU, Smith T et al. (2005) Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23: 5983–5992

    Article  PubMed  CAS  Google Scholar 

  33. Paridaens R, Biganzoli L, Bruning P et al. (2000) Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and treatment of Cancer Randomized study with cross-over. J Clin Oncol 18: 724–733

    PubMed  CAS  Google Scholar 

  34. Chan S, Friedrichs K, Noel D et al. (1999) Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer. J Clin Oncol 17: 2341

    PubMed  CAS  Google Scholar 

  35. Chan S, Friedrichs K, Noel D et al. (1997) A randomized phase III study of Taxotere (T) versus doxorubicin (D) in patients (pts) with metastatic breast cancer (MBC) who have failed an alkylating containing regimen: preliminary results (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 16: A540

    Google Scholar 

  36. Alba E, Ribelles N, Sevilla I et al. (2001) Adjuvant anthracycline therapy as a prognostic factor in metastatic breast cancer. Breast Cancer Res Treat 66: 33–39

    Article  PubMed  CAS  Google Scholar 

  37. Gennari A, Bruzzi P, Orlandini C et al. (2004) Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy. Br J Cancer 90: 962–967

    Article  PubMed  CAS  Google Scholar 

  38. Jones SE, Erban J, Overmoyer B et al. (2005) Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23: 5542–5551

    Article  PubMed  CAS  Google Scholar 

  39. Sjostrom J, Blomqvist C, Mouridsen H et al. (1999) Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 35: 1194–1201

    Article  PubMed  CAS  Google Scholar 

  40. Bonneterre J, Roche H, Monnier A et al. (2002) Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 87: 1210–1215

    Article  PubMed  CAS  Google Scholar 

  41. Nabholtz JM, Senn HJ, Bezwoda WR et al. (1999) Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 17: 1413–1424

    PubMed  CAS  Google Scholar 

  42. O’Shaughnessy J, Miles D, Vukelja S et al. (2002) Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results. J Clin Oncol 20: 2812–2823

    Article  PubMed  CAS  Google Scholar 

  43. Farquhar C, Marjoribanks J, Basser R, Hetrick S, Lethaby A (2005) High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer. Cochrane Database Syst Rev 3: CD003142

    PubMed  Google Scholar 

  44. Ejlertsen B, Pfeiffer P, Pedersen D et al. (1993) Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. Eur J Cancer 29A: 527–531

    Article  PubMed  CAS  Google Scholar 

  45. Gregory RK, Powles TJ, Chang JC, Ashley S (1997) A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast. Eur J Cancer 33: 2194–2197

    Article  PubMed  CAS  Google Scholar 

  46. Baselga J, Tripathy D, Mendelsohn J et al. (1996) Phase II study of weekly intravenous recombinant humanized anti-pl85HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14: 737–744

    PubMed  CAS  Google Scholar 

  47. Cobleigh MA, Vogel CL, Tripathy D et al. (1999) Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease. J Clin Oncol 17: 2639

    PubMed  CAS  Google Scholar 

  48. Vogel CL, Cobleigh MA, Tripathy D et al. (2002) Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer. J Clin Oncol 20: 719–726

    Article  PubMed  CAS  Google Scholar 

  49. Leyland-Jones B, Gelmon K, Ayoub JP et al. (2003) Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel. J Clin Oncol 21: 3965–3971

    Article  PubMed  CAS  Google Scholar 

  50. Slamon DJ, Leyland-Jones B, Shak S et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792

    Article  PubMed  CAS  Google Scholar 

  51. Robert N, Leyland-Jones B, Asmar L et al. (2006) Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2-Overexpressing Metastatic Breast Cancer. J Clin Oncol 24: 2786–2792

    Article  PubMed  CAS  Google Scholar 

  52. Perez EA, Suman VJ, Rowland KM et al. (2005) Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer 6: 425–432

    PubMed  CAS  Google Scholar 

  53. Marty M, Cognetti F, Maraninchi D et al. (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23: 4265–4274

    Article  PubMed  CAS  Google Scholar 

  54. Coates A, Gebski V, Bishop JF et al. (1987) Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 317: 1490–1495

    Article  PubMed  CAS  Google Scholar 

  55. Harris AL, Cantwell BM, Carmichael J et al. (1990) Comparison of shortterm and continuous chemotherapy (mitozantrone) for advanced breast cancer [see comments]. Lancet 335: 186–190

    Article  PubMed  CAS  Google Scholar 

  56. Muss HB, Case LD, Richards F et al. (1991) Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association [see comments]. N Engl J Med 325: 1342–1348

    Article  PubMed  CAS  Google Scholar 

  57. Falkson G, Gelman RS, Pandya KJ et al. (1998) Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol 16: 1669–1676

    PubMed  CAS  Google Scholar 

  58. Nooij MA, de Haes JC, Beex LV et al. (2003) Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. Eur J Cancer 39: 614–621

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre Léon Bérard Lyon, 28, rue Laënnec, 69008, Lyon

    J. -P. Guastalla

  2. Centre René Gauducheau, Boulevard Jacques-Monod, 44805, Nantes Saint-Herblain cedex

    M. Campone

  3. Centre Jean-Bernard, 9, rue Beauverger, 72000, Le Mans

    G. Ganem

  4. Service de pathologie, Centre René-Huguenin, 35, rue Dailly, 92210, Saint-Cloud

    J. -M. Guinebretière

  5. Centre René Huguenin, 35, rue Dailly, 92210, Saint-Cloud

    F. Lokiec

  6. Service d’oncologie digestive, CHU Nantes, Bd Jacques Monod, 44093, Nantes cedex 1

    A. Lortholary

  7. Département d’oncologie médicale UMR 599, Institut Paoli-Calmettes, 232, bd Sainte-Marguerite, 13273, Marseille cedex 9

    P. Viens

  8. Service d’oncologie, Hôpital Henri-Mondor, 51, av. du Mal de Lattre-de-Tassigny, 94010, Créteil

    L. Zelek

Authors
  1. J. -P. Guastalla
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Campone
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Ganem
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. -M. Guinebretière
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Lokiec
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Lortholary
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P. Viens
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L. Zelek
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag France, Paris

About this paper

Cite this paper

Guastalla, J.P. et al. (2007). Traitement médical du cancer du sein métastatique. In: Cancer du sein. Springer, Paris. https://doi.org/10.1007/978-2-287-71478-8_21

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-71478-8_21

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-71477-1

  • Online ISBN: 978-2-287-71478-8

Publish with us

Policies and ethics

Search

Navigation